Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
europe blog main
4
×
europe top stories
life sciences
national blog main
boston blog main
boston top stories
clinical trials
eli lilly
fda
indiana blog main
indiana top stories
national top stories
cancer
europe
new york blog main
new york top stories
san francisco blog main
san francisco top stories
abbvie
alkermes
allergan
arena pharmaceuticals
avapritinib
blueprint medicines
boehringer ingelheim
boston
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer drugs
capmatinib
cardiovascular disease
cariprazine
colorectal cancer
detroit blog main
detroit top stories
eisai
empagliflozin
felipe jain
What
drug
4
×
fda
4
×
approval
cancer
designed
medicine
patients
weight
address
alkermes
antipsychotic
approves
benefits
bid
blueprint
boehringer
carries
caveats
certain
commonly
diabetes
effect
eisai
eli
expand
fallen
favor
flags
gain
genetic
higher
incidence
ingelheim
latest
lilly
lorcaserin
loss
market
marketed
marketing
Language
unset
4
×
Current search:
drug
×
biotech
×
unset
×
fda
×
" europe blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
